Caliway Biopharmaceuticals C, TW0006919004

Caliway starts phase 3 trial: what it means for Caliway Biopharmaceuticals C stock

Published on 10/09/2026 at 12:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Caliway began a 320-person phase 3 trial on September 23, 2026. Caliway Biopharmaceuticals C stock had TWD 120.6 billion value on October 8, 2026.

Key points in brief

Caliway Biopharmaceuticals began a 320-participant phase 3 trial of CBL-514 on September 23, 2026.
The company had advanced through phase 3 amendments in Canada and phase 2 testing for CBL-514 in September.
Caliway Biopharmaceuticals stock was valued at TWD 120.6 billion on October 8, 2026, while the Taiwan quote stood at TWD 77.50.
The next reported results date is November 11, 2026.

Caliway Biopharmaceuticals C, TW0006919004, Illustration mit AI erstellt.

Caliway Biopharmaceuticals had started a 320-participant phase 3 trial of CBL-514 on September 23, 2026, according to Caliway Biopharmaceuticals. The development puts the companys lead drug into a larger late-stage test for abdominal fat reduction, while the stock had a TWD 120.6 billion market value on October 8, 2026.

What does 320 participants mean for development

The SUPREME-01 study is designed as a double-blind, randomized, placebo-controlled phase 3 trial in the United States and Canada. The company said the study will enroll about 320 participants and will assess patient-reported and clinician-reported abdominal fat ratings alongside MRI measurements, according to the September 23 release from Caliway Biopharmaceuticals.

The company also said animal data on combinations of CBL-514 with semaglutide and eloralintide had been selected for presentation at Obesity Week 2026 in November. That program addresses a commercial question beyond initial weight reduction: whether reducing fat cells can complement appetite-focused therapies and limit weight regain after treatment stops.

Three clinical steps in 2026

On September 21, 2026, Canada approved an amendment to Caliway's phase 3 CBL-514 study, as reported by Zonebourse. On September 22, the same source reported that CBL-514 had reached the primary objective in a phase 2 study for Dercum's disease.

The latest sequence is therefore three dated steps: a phase 3 amendment in Canada on September 21, phase 2 success for Dercum's disease on September 22, and first dosing in the 320-participant SUPREME-01 phase 3 study on September 23. The progression gives the pipeline a clear numerical timeline, but clinical development still carries execution and regulatory risk.

Dates and market reference

The next reported results date is November 11, 2026, according to Investing.com. The latest reported quarter ended June 2026, when revenue was TWD 3.57 million and earnings per share were minus TWD 0.14, versus revenue expectations of TWD 6.01 billion and earnings per share expectations of TWD 2.91, according to the same earnings page.

Caliway Biopharmaceuticals Co. Ltd. stock was last quoted at TWD 77.50 on the Taiwan Stock Exchange on October 8, 2026 at 1:30 p.m. TST, down 0.77 percent from TWD 78.10. Its 52-week range was TWD 75.10 to TWD 188.00, putting the quote 2.40 percent above the low and 58.78 percent below the high.